Medicine

Merck Completes Acquisition of Investigational Bispecific Antibody Therapy from Curon Biopharmaceutical

admin October 2, 2024

CN201 is currently being evaluated in Phase I and Phase Ib/II clinical trials for relapsed or refractory non-Hodgkin lymphoma and B-cell acute lymphocytic leukemia.

LEAVE A RESPONSE Cancel reply

admin

View all posts

Medicine

Quantifying the Benefits of AI-Powered Patient Adherence Programs

admin December 9, 2024

Medicine

FDA Approves Biocon Biologics’ Yesafili, an Eylea Biosimilar, for the Treatment of Multiple Ophthalmic Conditions

admin May 22, 2024

Medicine

Thriving ‘Beyond the Pill’: Closing Key Gap in Patient Support

admin August 14, 2024

Medicine

FDA Approves Bristol Myers Squibb’s Cobenfy for Schizophrenia

admin September 28, 2024

Kwarlay.com

Kwarlay.com

Merck Completes Acquisition of Investigational Bispecific Antibody Therapy from Curon Biopharmaceutical

LEAVE A RESPONSE Cancel reply

admin

Quantifying the Benefits of AI-Powered Patient Adherence Programs

FDA Approves Biocon Biologics’ Yesafili, an Eylea Biosimilar, for the Treatment of Multiple Ophthalmic Conditions

Thriving ‘Beyond the Pill’: Closing Key Gap in Patient Support

FDA Approves Bristol Myers Squibb’s Cobenfy for Schizophrenia

Recent Posts

Archives

Categories

Merck Completes Acquisition of Investigational Bispecific Antibody Therapy from Curon Biopharmaceutical

LEAVE A RESPONSE Cancel reply

admin

You Might Also Like

Quantifying the Benefits of AI-Powered Patient Adherence Programs

FDA Approves Biocon Biologics’ Yesafili, an Eylea Biosimilar, for the Treatment of Multiple Ophthalmic Conditions

Thriving ‘Beyond the Pill’: Closing Key Gap in Patient Support

FDA Approves Bristol Myers Squibb’s Cobenfy for Schizophrenia

Recent Posts

Archives

Categories